COVID-19 and chronic kidney disease: peculiarities of treatment
Journal: Ukrainian Journal of Nephrology and Dialysis (Vol.2, No. 74)Publication Date: 2022-06-15
Authors : O. Chernatska; A. Grek;
Page : 83-89
Keywords : chronic kidney disease; COVID-19; statins; angiotensin-converting enzyme inhibitors;
Abstract
The present study aimed to characterize the management of patients with chronic kidney disease with concomitant COVID-19. Articles published in 2019-2021 in the PubMed, Scopus, and Google Scholar electronic databases were analyzed.
As a result of this review, the following particularities of COVID-19 treatment in chronic kidney disease could be summarized. It is obligatory to continue treatment with renin-angiotensin-aldosterone system inhibitors in patients with chronic kidney disease and COVID-19. Lisinopril is considered used for avoiding the elevated renal expression of angiotensin-converting enzyme 2. Spironolactone can prevent acute lung injuries and is reasonable if the triple combination of drugs for reducing blood pressure is not effective. Low-dose rosuvastatin therapy is recommended for patients with COVID-19 and chronic kidney disease stages 3-5 treated with antiretroviral drugs such as lopinavir and ritonavir, remdesivir. Ezetimibe is reasonable to use in case of ineffective higher doses of statins and to decrease hospitalization risk.
Other Latest Articles
- Epidemiology and course features of acute kidney injury in Ukrainian children
- HLA as risk and protection antigens against urinary tract diseases
- Chronic inflammation in hemodialysis patients with secondary hyperparathyroidism
- Features of the prevalence of chronic cystitis among adolescents
- Morphological pattern of non-diabetic nephropathy in type 2 diabetes mellitus patients
Last modified: 2022-12-22 21:02:20